IRS2 (Insulin receptor substrate 2)

News alerts, weekly reports and conference planners

Entrez ID:

IRS2 T1156M	Colorectal Cancer	IRS2 T1156M	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
IRS2 amplification	Colorectal Cancer	IRS2 amplification	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
IRS2 mutation	Colorectal Cancer	IRS2 mutation	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
IRS2 amplification	Colorectal Cancer	IRS2 amplification	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D
IRS2 amplification + KRAS mutation	Colorectal Cancer	IRS2 amplification + KRAS mutation	Colorectal Cancer	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D	BMS-754807 Sensitive: D – Preclinical BMS-754807 Sensitive : D

Associations(5)